TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Bladder cancer is characterized by high invasiveness and metastatic potential, often leading to poor patient prognosis.
• Epithelial-to-mesenchymal transition (EMT) is a key driver of bladder cancer invasion and metastasis.
• The E3 ubiquitin ligase tumor necrosis factor receptor-associated factor 4 (TRAF4) is implicated as a tumor promoter in various cancers.

Purpose of the Study:

• To investigate the role of TRAF4 in bladder cancer progression and its association with patient survival.
• To elucidate the mechanisms by which TRAF4 influences bladder cancer cell invasion and metastasis.

Main Methods:

• Analysis of TRAF4 expression in bladder cancer patients and cell lines.
• Investigation of TRAF4 epigenetic regulation and post-translational modification (e.g., phosphorylation by ERK).
• Functional studies manipulating TRAF4 expression to assess its impact on EMT markers, cell invasion, and signaling pathways (BMP/SMAD, NF-κB).
• Assessment of TRAF4's interaction with SMURF1 and its effect on proteasomal degradation.

Main Results:

• Low TRAF4 expression is significantly associated with poor overall survival in bladder cancer patients.
• TRAF4 expression is epigenetically silenced and reduced by ERK-mediated phosphorylation in bladder cancer cells.
• TRAF4 expression is inversely correlated with EMT markers and invasiveness; TRAF4 suppresses EMT and invasion.
• High TRAF4 expression enhances BMP/SMAD signaling and inhibits NF-κB signaling, partly via targeting SMURF1 for degradation.
• TRAF4 positively correlates with phospho-SMAD1/5 and negatively with phospho-NFκb-p65 in patient samples.

Conclusions:

• TRAF4 acts as a tumor suppressor in bladder cancer, contrary to its role in other cancers.
• TRAF4 regulates bladder cancer cell invasion and metastasis by modulating EMT and key signaling pathways.
• TRAF4 is identified as a potential therapeutic target or predictive biomarker for bladder cancer progression.